{"id":"W6977698662","doi":"10.6084/m9.figshare.c.7367241.v1","title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study","year":2024,"lang":"en","type":"other","venue":"Figshare","topic":"Probability and Statistical Research","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Pembrolizumab; Placebo; Lung cancer; Immunotherapy; Phases of clinical research; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002133551,0.00176064,0.003580672,0.0006655523,0.0004003387,0.000975468,0.0009154755,0.001561697,0.004652689],"category_scores_gemma":[0.001236417,0.0008072266,0.00146372,0.0003773887,0.001148271,0.0009570459,0.0003782227,0.002256873,0.0008824575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006934128,"about_ca_system_score_gemma":0.0009760328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004662713,"about_ca_topic_score_gemma":0.0007556065,"domain_scores_codex":[0.999155,0.0004446475,0.00005662193,0.0001578521,0.00007513172,0.0001107535],"domain_scores_gemma":[0.9991388,0.0002635756,0.0001862323,0.00006992788,0.00006108602,0.0002802656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970642,0.01718517,0.0003015815,0.0002624737,0.0003981633,0.00002095564,0.00002079805,0.0001994926,0.003811875,0.00004487023,0.0002051402,0.00690754],"study_design_scores_gemma":[0.8125006,0.1843837,0.001110719,0.000015424,0.0003337409,0.00002222689,0.00001168642,0.0004133705,0.0008012666,0.00006739033,0.0003285039,0.00001125694],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901553,0.002312525,0.0006272204,0.0002858681,0.0004107874,0.004448285,0.000532613,0.000094025,0.00113335],"genre_scores_gemma":[0.9887516,0.001408546,0.001515059,0.0005009747,0.000454627,0.004623035,0.0004811405,0.00001588577,0.002249131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004652689,"threshold_uncertainty_score":0.01556474,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2081530474279305,"score_gpt":0.4372120831167093,"score_spread":0.2290590356887788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}